Lowell Dashefsky was appointed general counsel of Advance Nanotech (New York), a provider of financing and support services to drive the commercialization of nanotechnology discoveries. For the past five years, Dashefsky has been an associate at Shearman & Sterling, where he was a member of the Intellectual Property Transactions group.

Steve Okland has joined Avitar (Canton, Massachusetts) as vice president of sales. His career includes a 12-year tenure at Boston Scientific, where he most recently served as director of sales for Boston Scientific/Microvasive. Avitar manufactures ORALscreen, a non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as Hydrasorb, an absorbent topical dressing for moderate to heavy exudating wounds. The company also is developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in vitro diagnostics market.

Tom Watlington, executive vice president and chief operating officer of Biosite (San Deigo), will leave the company by the end of 1Q06 to assume an executive operating role at several portfolio companies of Sanderling Ventures. Watlington, who joined Biosite in 1996, just prior to the company's initial public offering, led commercialization of a string of new products, including the Triage BNP Test, which the company said changed the practice of heart failure diagnosis and enabled Biosite to become a leader in cardiovascular in vitro diagnostic testing in 2004.

Edward Wong has been appointed vice president of global R&D and engineering at the Del Medical Systems business segment of Del Global Technologies (Valhalla, New York). Wong will be based in the Franklin Park, Illinois, office. He comes to Del Medical from Siemens Medical Systems, where he has served as vice president of global engineering, Siemens X-Ray Division. Del Global Technologies manufactures medical imaging and diagnostic systems consisting of stationary and portable X-ray systems, radiographic/fluoroscopic systems, dental imaging systems and high-voltage power conversion subsystems for medical and other critical industrial applications.

Robert Mignatti has joined Exagen Diagnostics (Albuquerque, New Mexico) as president and chief operating officer. Exagen CEO Jim McClintic, who joined the company in October, will continue to guide the company's strategic direction. Mignatti comes to Exagen with 33 years of laboratory and kit-based diagnostics experience, including senior management and sales roles at Esoterix, Allergy Testing Laboratory, Kallestad Diagnostics and Baxter International. Last year, McClintic and Mignatti led the sale of Esoterix to Laboratory Corp. of America for $150 million. Exagen Diagnostics discovers, validates and productize small sets of genomic markers for use in oncology, infectious disease and other indications.

• FoxHollow Technologies (Redwood City, California), manufacturer of the SilverHawk Plaque Excision System – a minimally invasive device for the treatment of peripheral artery disease – reported a pair of management changes. Ron Steckel has been named chief operating officer of the company, while Richard Zimmer has been named vice president of sales. They replace David Martin and Bill Hoffman, respectively. Steckel has been FoxHollow's senior vice president of operations and research & development since July 2004 and has more than 30 years of experience in medical technology companies. Zimmer, who has two decades of healthcare industry sales experience, joined FoxHollow more than two years ago and has served as director of sales since October. The company said the transition was due to its new strategic initiatives.

No Comments